A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

July 27, 2027

Study Completion Date

July 27, 2027

Conditions
Neoplasms, Head and Neck
Interventions
DRUG

Dostarlimab

Dostarlimab will be administered.

DRUG

Belrestotug

Belrestotug will be administered.

DRUG

Nelistotug

Nelistotug will be administered.

DRUG

Remzistotug

Remzistotug will be administered.

Trial Locations (113)

500

GSK Investigational Site, Changhua

704

GSK Investigational Site, Tainan City

3000

GSK Investigational Site, Santa Fe

4400

GSK Investigational Site, Nyíregyháza

5000

GSK Investigational Site, Córdoba

5400

GSK Investigational Site, San Juan

6000

GSK Investigational Site, Kecskemét

7624

GSK Investigational Site, Pécs

9024

GSK Investigational Site, Győr

10002

GSK Investigational Site, Taipei

11217

GSK Investigational Site, Taipei

12200

GSK Investigational Site, Berlin

12462

GSK Investigational Site, Haidari - Athens

13005

GSK Investigational Site, Marseille

13620

GSK Investigational Site, Seongnam-si Gyeonggi-do

14075

GSK Investigational Site, Caen

16132

GSK Investigational Site, Genova

20089

GSK Investigational Site, Rozzano MI

20133

GSK Investigational Site, Milan

20246

GSK Investigational Site, Hamburg

20520

GSK Investigational Site, Turku

23007

GSK Investigational Site, Jaén

28010

GSK Investigational Site, Madrid

28034

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28100

GSK Investigational Site, Novara

28223

GSK Investigational Site, Pozuelo de AlarcOn Madr

30463

GSK Investigational Site, Bucharest

33075

GSK Investigational Site, Bordeaux

34662

GSK Investigational Site, Istanbul

35040

GSK Investigational Site, Izmir

35128

GSK Investigational Site, Padua

35392

GSK Investigational Site, Giessen

37007

GSK Investigational Site, Salamanca

39008

GSK Investigational Site, Santander

40139

GSK Investigational Site, Bologna

42601

GSK Investigational Site, Daegu

43210

GSK Investigational Site, Columbus

45122

GSK Investigational Site, Essen

46009

GSK Investigational Site, Valencia

50009

GSK Investigational Site, Zaragoza

50134

GSK Investigational Site, Florence

52074

GSK Investigational Site, Aachen

52242

GSK Investigational Site, Iowa City

53226

GSK Investigational Site, Milwaukee

55236

GSK Investigational Site, Thessaloniki

60488

GSK Investigational Site, Frankfurt

63021

GSK Investigational Site, St Louis

70124

GSK Investigational Site, Bari

75005

GSK Investigational Site, Paris

76038

GSK Investigational Site, Rouen

80131

GSK Investigational Site, Napoli

89075

GSK Investigational Site, Ulm

93053

GSK Investigational Site, Regensburg

94805

GSK Investigational Site, Villejuif

110283

GSK Investigational Site, Piteşti

200508

GSK Investigational Site, Craiova

200542

GSK Investigational Site, Craiova

407280

GSK Investigational Site, Floreşti

410469

GSK Investigational Site, Oradea

500283

GSK Investigational Site, Brasov

700483

GSK Investigational Site, Iași

720214

GSK Investigational Site, Suceava

06511

GSK Investigational Site, New Haven

C1426ABP

GSK Investigational Site, Buenos Aires

C1181ACH

GSK Investigational Site, Capital Federal

C1056ABI

GSK Investigational Site, Ciudad Autonoma de Bueno

B1602DQD

GSK Investigational Site, Florida

M5500AYB

GSK Investigational Site, Mendoza

09060-650

GSK Investigational Site, Santo André

01221-020

GSK Investigational Site, São Paulo

01246-000

GSK Investigational Site, São Paulo

T2N 5G2

GSK Investigational Site, Calgary

T6G 1Z2

GSK Investigational Site, Edmonton

M4N 3M5

GSK Investigational Site, Toronto

M5G 2M9

GSK Investigational Site, Toronto

H3T 1E2

GSK Investigational Site, Montreal

Unknown

GSK Investigational Site, Herlev

GSK Investigational Site, Marousi

04103

GSK Investigational Site, Leipzig

00144

GSK Investigational Site, Roma

00168

GSK Investigational Site, Roma

464-8681

GSK Investigational Site, Aichi

277-8577

GSK Investigational Site, Chiba

650-0017

GSK Investigational Site, Hyōgo

541-8567

GSK Investigational Site, Osaka

350-1298

GSK Investigational Site, Saitama

411-8777

GSK Investigational Site, Shizuoka

104-0045

GSK Investigational Site, Tokyo

0379

GSK Investigational Site, Oslo

43-300

GSK Investigational Site, Bielsko-Biala

44-102

GSK Investigational Site, Gliwice

40-514

GSK Investigational Site, Katowice

31-826

GSK Investigational Site, Krakow

37-700

GSK Investigational Site, Przemyśl

08-110

GSK Investigational Site, Siedlce

04-141

GSK Investigational Site, Warsaw

2801-951

GSK Investigational Site, Almada

1649-035

GSK Investigational Site, Lisbon

4099-001

GSK Investigational Site, Porto

4200-072

GSK Investigational Site, Porto

013823

GSK Investigational Site, Bucharest

020142

GSK Investigational Site, Bucharest

022328

GSK Investigational Site, Bucharest

030171

GSK Investigational Site, Bucharest

03722

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul

443-721

GSK Investigational Site, Suwon Kyunggi-do

08023

GSK Investigational Site, Barcelona

08035

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona

06100

GSK Investigational Site, Ankara

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

iTeos Therapeutics

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY